INDV

MKT CAP:$4B

Indivior Pharmaceuticals Inc

Market Cap

$4B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$33.15-$2.58 (-7.23%)

Apr 23, 2026

Company Details

Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and...

CEO

Joseph J. Ciaffoni

IPO Date

Dec 29, 2014

Website

www.indivior.com

Key Metrics TTM

Revenue

$1.1B

+16.6% YoY

Net Income

-$16M

EPS (Diluted)

-$0.04

Free Cash Flow

-$46M

Revenue / Share

$9.15

Gross Margin

83.0%

Operating Margin

1.4%

Net Margin

-1.4%

FCF Margin

-4.1%

P/S

3.7x

P/E

—

Earnings Reports

Q3 2025

Apr 30, 2026

PENDING

FY 2025

Feb 26, 2026

$1.2B+4.3%EPS $1.64

Q2 2025

Jul 31, 2025

$302MEPS $0.14

Q1 2025

May 1, 2025

$266MEPS $0.38

FY 2024

Mar 3, 2025

$1.2B+8.7%EPS $0.01

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$221M	$183M	$63M
Q3 22	$232M	$192M	$56M
Q4 22	$242M	$198M	-$258M
Q2 23	$276M	$226M	$61M
Q3 23	$271M	$225M	-$183M
Q4 23	$293M	$242M	$61M
Q1 25	$266M	$222M	$66M
Q2 25	$302M	$250M	$72M

Valuation

Quarter	P/S	P/E
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q2 23	3.3x	—
Q3 23	2.9x	—
Q4 23	2.0x	—
Q1 25	1.1x	251.6x
Q2 25	1.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	$29M	$27M
Q3 22	$60M	$58M
Q4 22	-$17M	-$18M
Q2 23	-$20M	-$21M
Q3 23	$21M	$19M
Q4 23	-$280M	-$284M
Q1 25	$75M	$70M
Q2 25	$166M	$148M

Capital Expenditures

Quarter	CapEx
Q2 22	$2M
Q3 22	$2M
Q4 22	$1M
Q2 23	$1M
Q3 23	$2M
Q4 23	$4M
Q1 25	$5M
Q2 25	$18M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 23	+22.6%	+187.3%
Q4 23	+26.3%	+31.8%
Q1 25	+9.9%	-60.0%
Q2 25	+9.4%	+7.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$0	0.0%
Q3 22	$0	0.0%
Q4 22	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$0	0.0%
Q1 25	$6M	2.3%
Q2 25	$8M	2.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 22	$14M	$54M	$55M
Q3 22	$20M	$62M	$53M
Q4 22	$29M	$374M	$58M
Q2 23	$32M	$75M	$58M
Q3 23	$18M	$390M	—
Q4 23	$29M	$89M	$68M
Q1 25	$22M	$65M	$67M
Q2 25	$21M	$158M	—

Revenue Segments

Quarter	Reportable Segment
Q1 25	$266M
Q2 25	$302M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$874M	$65M	$939M
Q2 22	$859M	$77M	$936M
Q3 22	$821M	$97M	$918M
Q4 22	$778M	$120M	$898M
Q1 23	$588M	$117M	$705M
Q2 23	$592M	$97M	$689M
Q3 23	$610M	$112M	$722M
Q4 23	$316M	$94M	$410M
Q1 24	$248M	$82M	$330M
Q2 24	$302M	$77M	$379M
Q3 24	$288M	$30M	$318M
Q4 24	$319M	$1M	$320M
Q1 25	$372M	$1M	$373M
Q2 25	$510M	$0	$510M
Q3 25	$445M	$0	$445M
Q4 25	$195M	$0	$195M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	140M	—	—
Q3 22	146M	+4.8%	—
Q4 22	136M	-6.8%	—
Q2 23	143M	+4.6%	—
Q3 23	138M	-3.5%	-1.4%
Q4 23	142M	+3.1%	-3.1%
Q1 25	124M	-12.9%	-9.4%
Q2 25	124M	0.0%	-13.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$251.7K	1K
Q1 25	$253.1K	1K
Q2 25	$287.3K	1K

Revenue / Employee